Li Jinyu, Wang Wei, Feng Guiyu, Du Jian, Kang Shengqian, Li Zhe, Zhu Weifeng, Shang Hongcai
Key Laboratory of Chinese Internal Medicine of the Ministry of Education, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing 100700, China.
Key Laboratory of Modern Chinese Medicine Preparation of Ministry of Education, Jiangxi University of Traditional Chinese Medicine, Nanchang, Jiangxi 330004, China.
Evid Based Complement Alternat Med. 2020 Sep 15;2020:6957825. doi: 10.1155/2020/6957825. eCollection 2020.
To evaluate the effects and medication safety of Duhuo Jisheng Decoction (DHJSD) alone or as a combination therapy with other interventions on the related clinical index in postmenopausal osteoporosis condition.
Search in CNKI, WanFang, CBM, VIP, PubMed, EMBASE, and Cochrane Library databases and randomized controlled trials where at least one group received any form of DHJSD for postmenopausal osteoporosis condition. Risk of bias was based on the Cochrane handbook, the quality of evidence was assessed by the GRADEpro online, and analyses were performed by RevMan 5.3 software.
Eight studies were enrolled with 650 participants. DHJSD alone or with other interventions had a significant effect on BMD of the lumbar spine (MD = 0.46, 95%CI (0.24, 0.68), < 0.0001), E2 (SMD = 0.49, 95%CI (0.30, 0.68), < 0.0001), and clinical effectiveness (OR = 5.07, 95%CI (3.07, 8.35), < 0.0001). However, no effect at BGP (MD = -0.84, 95%CI (-1.69, 0.00), =0.05) was seen.
The pooled estimate suggested that DHJSD combined with conventional medical therapies has a certain clinical curative effect on postmenopausal osteoporosis. However, considering the unsatisfactory quality of included trials, more high-quality trials are needed to elucidate this issue.
评估独活寄生汤单独使用或与其他干预措施联合使用对绝经后骨质疏松症相关临床指标的影响及用药安全性。
检索中国知网、万方、中国生物医学文献数据库、维普、PubMed、EMBASE和Cochrane图书馆数据库，纳入至少一组接受任何形式独活寄生汤治疗绝经后骨质疏松症的随机对照试验。根据Cochrane手册评估偏倚风险，通过GRADEpro在线评估证据质量，并使用RevMan 5.3软件进行分析。
共纳入8项研究，650名参与者。独活寄生汤单独使用或与其他干预措施联合使用对腰椎骨密度（MD = 0.46，95%CI（0.24，0.68），P < 0.0001）、雌二醇（SMD = 0.49，95%CI（0.30，0.68），P < 0.0001）和临床疗效（OR = 5.07，95%CI（3.07，8.35），P < 0.0001）有显著影响。然而，对骨钙素（MD = -0.84，95%CI（-1.69，0.00），P = 0.05）未见影响。
汇总估计表明，独活寄生汤联合传统药物治疗对绝经后骨质疏松症有一定临床疗效。然而，考虑到纳入试验质量不尽人意，需要更多高质量试验来阐明这一问题。
